Beigene Ltd (NASDAQ:BGNE) CMO Jane Huang sold 2,079 shares of the company’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $200.29, for a total transaction of $416,402.91. Following the sale, the chief marketing officer now directly owns 326,247 shares in the company, valued at $65,344,011.63. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Jane Huang also recently made the following trade(s):
- On Monday, June 29th, Jane Huang sold 1,935 shares of Beigene stock. The stock was sold at an average price of $190.83, for a total transaction of $369,256.05.
- On Monday, June 8th, Jane Huang sold 631 shares of Beigene stock. The shares were sold at an average price of $170.84, for a total value of $107,800.04.
- On Friday, May 29th, Jane Huang sold 1,500 shares of Beigene stock. The shares were sold at an average price of $163.86, for a total transaction of $245,790.00.
- On Wednesday, April 29th, Jane Huang sold 1,500 shares of Beigene stock. The stock was sold at an average price of $162.30, for a total value of $243,450.00.
- On Thursday, April 16th, Jane Huang sold 1,500 shares of Beigene stock. The stock was sold at an average price of $160.00, for a total transaction of $240,000.00.
Beigene stock opened at $188.40 on Wednesday. The stock has a 50-day simple moving average of $171.15 and a 200 day simple moving average of $160.73. The company has a current ratio of 7.96, a quick ratio of 7.89 and a debt-to-equity ratio of 0.08. Beigene Ltd has a 52 week low of $114.41 and a 52 week high of $210.35.
Beigene (NASDAQ:BGNE) last released its quarterly earnings data on Monday, May 11th. The company reported ($4.70) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($4.85) by $0.15. Beigene had a negative return on equity of 68.64% and a negative net margin of 284.45%. The company had revenue of $52.06 million during the quarter, compared to analysts’ expectations of $27.00 million. On average, sell-side analysts anticipate that Beigene Ltd will post -19.99 earnings per share for the current year.
A number of hedge funds have recently added to or reduced their stakes in the business. Capital International Investors increased its holdings in shares of Beigene by 25.4% in the first quarter. Capital International Investors now owns 5,706,609 shares of the company’s stock valued at $702,544,000 after purchasing an additional 1,155,679 shares during the last quarter. Primecap Management Co. CA boosted its holdings in shares of Beigene by 70.2% during the 1st quarter. Primecap Management Co. CA now owns 1,700,021 shares of the company’s stock worth $209,290,000 after buying an additional 701,444 shares during the period. Norges Bank bought a new stake in shares of Beigene during the 4th quarter worth about $67,449,000. Sands Capital Management LLC grew its stake in Beigene by 102.7% in the 1st quarter. Sands Capital Management LLC now owns 338,366 shares of the company’s stock valued at $41,656,000 after buying an additional 171,443 shares during the last quarter. Finally, Pictet Asset Management Ltd. raised its holdings in Beigene by 58.0% in the 4th quarter. Pictet Asset Management Ltd. now owns 268,234 shares of the company’s stock valued at $3,443,000 after acquiring an additional 98,452 shares during the period. 63.78% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have recently issued reports on BGNE shares. SVB Leerink increased their price objective on shares of Beigene from $207.00 to $210.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 3rd. Cowen reissued a “buy” rating and issued a $200.00 target price on shares of Beigene in a research report on Tuesday, March 3rd. ValuEngine raised shares of Beigene from a “hold” rating to a “buy” rating in a research note on Tuesday, March 3rd. Zacks Investment Research raised shares of Beigene from a “hold” rating to a “buy” rating and set a $182.00 price objective on the stock in a research report on Friday, May 29th. Finally, Morgan Stanley raised their target price on shares of Beigene from $184.00 to $190.00 and gave the company an “overweight” rating in a research report on Thursday, May 28th. Four investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Beigene currently has a consensus rating of “Buy” and an average target price of $200.73.
Beigene Company Profile
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Further Reading: Why are analyst ratings important in trading stocks?
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.